skip to navigation

PMD Healthcare PMD Healthcare

News

PMD Healthcare achieves positive study results in Cystic Fibrosis

Share: Share on LinkedIn

ALLENTOWN, Pa.April 20, 2017 /PRNewswire/ — PMD Healthcare announced today positive results from a pediatric Cystic Fibrosis study demonstrating the feasibility of home Spirometry using Spiro PD.  The study was published in Global Pediatric Health Volume 4: 1–6.

Cystic Fibrosis is a chronic, life shortening illness that affects approximately 1 in 3,400 people at birth in the United States.   People with Cystic Fibrosis take multiple types of medication, and complete daily treatment tasks to manage their illness.  Both patients and healthcare providers recognize that adherence to complicated and numerous regimens are a daily challenge for patients.

This two-phase study set out to understand the barriers and motivators to adherence in Cystic Fibrosis, and to determine the feasibility of home monitoring using Spiro PD and its impact on adherence. Common health outcomes and quality of life measures including; FEV1, body mass index (BMI) and treatment burden scores were evaluated to compare the intervention group versus a control group.  31 of the 40 patients (77.5%) surveyed in phase one of the study endorsed frequent monitoring of pulmonary function tests (PFT’s) and 29 of the patients supported the use of home spirometry as an adherence intervention.  In phase two of the study 94.7% of the patients were adherent to home spirometry using Spiro PD.  In addition to a strong endorsement for home pulmonary function test  (PFT’s) monitoring, patients forced expiratory volume (FEV1) percent predicted increased from 74.3% at baseline to 77% predicted at the end of the study.  Findings described tangible feedback from PFT’s a strong adherence motivator by study participants. Likewise, medication reminders provided by the Spiro PD device were also identified as an adherence motivator.  PFT’s, body mass index and treatment burden scores all improved in the intervention versus the control group.

“This study offers further evidence of how remote patient monitoring and supportive adherence reminders, can have a positive impact on patient self- management and play a pivotal role in treatment success,” said Steve Sullivan Executive Vice President at PMD Healthcare.

Founded in 2010, PMD Healthcare is a Medical Device, Digital Health, and Chronic Care Management Service Company with a mission dedicated to creating innovative solutions that empower people to improve their healthcare and quality of life. With that intent focus, PMD developed the first ever personal spirometer, Spiro PD, which was approved by the FDA in 2011.  Since then, Spiro PD has been widely adopted by leading healthcare institutions and has become the standard of care for remote monitoring of lung function for patients who have undergone lung transplant surgery and for patients with cystic fibrosis.

PMD is now launching several new products including its second-generation spirometer, Spiro PD 2.0, and its HIPPA compliant Wellness Management System (WMS). The introduction of the second-generation Spiro PD 2.0 device and HIPPA compliant Wellness Management System (WMS) introduces the use of telemonitoring technology via WIFI to connect patients, providers and caregivers anytime and anywhere.

To learn more about PMD Healthcare, please visit www.MyPMD.com.